News · 26 weeks87+9%
2026-03-012026-08-23
Mix4290d
- Insider22(52%)
- SEC Filings8(19%)
- Other8(19%)
- Earnings2(5%)
- Offering1(2%)
- Analyst1(2%)
Latest news
25 items- PRCastle Biosciences to Participate in Upcoming Investor ConferencesFRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m. Eastern time.A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/news-events/ir-events. A replay of the webcast will be available following the conclusion of the live broadcast.Castle will also be available for one-on-one investor meetings during the 10th annual L
- INSIDERChief Commercial Officer Juvenal Tobin W sold $51,191 worth of shares (1,730 units at $29.59) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 75,964 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Financial Officer Stokes Frank sold $741,511 worth of shares (24,908 units at $29.77), decreasing direct ownership by 41% to 35,177 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 1,100 shares at a strike of $2.39 and sold $217,105 worth of shares (7,232 units at $30.02) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRCastle Biosciences Approved for Dual Listing on Nasdaq TexasFRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL.""Castle was founded in Texas and remains deeply connected to the state's communities, talent and innovation ecosystem," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Our dual
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- SECSEC Form 8-A12B filed by Castle Biosciences Inc.8-A12B - CASTLE BIOSCIENCES INC (0001447362) (Filer)
- INSIDERChief Commercial Officer Juvenal Tobin W sold $49,945 worth of shares (1,301 units at $38.39) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 77,694 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 22,902 shares at a strike of $2.39 and sold $1,212,230 worth of shares (39,016 units at $31.07) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Operating Officer Oelschlager Kristen M sold $255,622 worth of shares (8,586 units at $29.77) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 13,288 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Commercial Officer Juvenal Tobin W sold $556,175 worth of shares (19,040 units at $29.21) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 78,995 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 17,144 shares at a strike of $2.39 and sold $867,451 worth of shares (28,646 units at $30.28) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- SECSEC Form 10-Q filed by Castle Biosciences Inc.10-Q - CASTLE BIOSCIENCES INC (0001447362) (Filer)
- SECCastle Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)
- PRCastle Biosciences Reports Second Quarter 2026 ResultsDelivered Q2 2026 revenue of $103.5 millionQ2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 32% over Q2 2025Raising full-year 2026 revenue guidance to $365-375 million from $345-355 millionConference call and webcast today at 4:30 p.m. ETFRIENDSWOOD, Texas, July 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter ended June 30, 2026."The Castle Biosciences team delivered another outstanding quarter," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We beli
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $237,682 worth of shares (9,836 units at $24.16) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRCastle Biosciences to Present at the Canaccord Genuity 46th Annual Growth ConferenceFRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, Aug. 12, 2026, at 11:30 a.m. Eastern time.A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/news-events/ir-events. A replay of the webcast will be available following the conclusion of the live broadcast.About Castle BiosciencesCastle Biosciences (NASDAQ:CSTL) is a leading diagno
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $95,622 worth of shares (4,172 units at $22.92) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRCastle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ TestApproval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD)."We are proud to announce the final approval
- PRCastle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the close of market on Thursday, July 30, 2026.Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.Webcast DetailsThe live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/. Please access the web
- INSIDERChief Operating Officer Oelschlager Kristen M sold $209,650 worth of shares (8,586 units at $24.42) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 21,874 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J sold $238,916 worth of shares (9,836 units at $24.29) as part of a pre-agreed trading plan and exercised 6,214 shares at a strike of $2.39 (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- PRDecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node BiopsyNewly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogramPatients classified as low risk by the i31-SLNB result had a 2.6% observed SLN positivity rate, falling well below the National Comprehensive Cancer Network (NCCN) 5% threshold used to consider avoiding sentinel lymph node biopsy (SLNB), compared with a 5.8% observed positivity rate for the MIA nomogramFRIENDSWOOD, Texas, June 25, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient car
CSTL FAQ
7 questionsWhat does Castle Biosciences Inc. do?
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test...Where does CSTL stock trade?
Castle Biosciences Inc. (CSTL) is listed on NASDAQ.What sector and industry is CSTL in?
Castle Biosciences Inc. operates in the Health Care sector, Medical Specialities industry.When did Castle Biosciences Inc. go public?
Castle Biosciences Inc. (CSTL) completed its IPO in 2019.What are analysts saying about CSTL?
Castle Biosciences Inc. has had 6 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $4000.00 price target on 2026-06-25. Recent price targets range from $2500.00 to $4000.00.What companies are similar to CSTL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare CSTL side-by-side with any of them on Quantisnow.How can I track CSTL on Quantisnow?
Quantisnow aggregates Castle Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CSTL to receive live email and push alerts on every new disclosure.